Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sandrine Faivre

Showing results (21-30 of 139) with videos related to

Pageof 14
Sort By:
Presse Medicale (Paris, France : 1983)|August 1, 2002
[New drugs in bronchial cancer]Catherine Delbaldo, Sandrine Faivre, Christian Monnerat, et al.
Endocrinology and Metabolism Clinics of North America|November 25, 2010
Novel anticancer agents in clinical trials for well-differentiated neuroendocrine tumorsSandrine Faivre, Marie-Paule Sablin, Chantal Dreyer, et al.
Lung Cancer (Amsterdam, Netherlands)|October 11, 2007
Could we expect to improve survival in small cell lung cancer?Ghassan El Maalouf, Jean-Michel Rodier, Sandrine Faivre, et al.
Therapie|June 22, 2007
[Irinotecan and liver dysfunctions]Marie-Paule Sablin, Christophe Le Tourneau, Sandrine Faivre, et al.
Presse Medicale (Paris, France : 1983)|April 10, 2010
[Targeted therapies in hepatocellular carcinoma]Mohamed Bouattour, Hélène Marijon, Chantal Dreyer, et al.
Molecular Cancer Therapeutics|December 7, 2002
Cellular and molecular pharmacology of oxaliplatinEric Raymond, Sandrine Faivre, Stephen Chaney, et al.
La Revue Du Praticien|January 5, 2011
[Targeted therapies in colorectal cancer]Marie-Paule Sablin, Chantal Dreyer, Camélia Colichi, et al.
Biochemical Pharmacology|June 27, 2003
DNA strand breaks and apoptosis induced by oxaliplatin in cancer cellsSandrine Faivre, Denise Chan, Richard Salinas, et al.
Bulletin Du Cancer|July 12, 2011
[PI3K-AKT-mTOR pathway and cancer]Laetitia Coutte, Chantal Dreyer, Marie-Paule Sablin, et al.
Annals of Surgical Oncology|April 14, 2009
Preoperative liver hypertrophy induced by portal flow occlusion before major hepatic resection for colorectal metastases can be impaired by bevacizumabBéatrice Aussilhou, Safi Dokmak, Sandrine Faivre, et al.
Pageof 14

Showing results (21-30 of 139) with videos related to

Sort By:
Pageof 14
Presse Medicale (Paris, France : 1983)|August 1, 2002
[New drugs in bronchial cancer]Catherine Delbaldo, Sandrine Faivre, Christian Monnerat, et al.
Endocrinology and Metabolism Clinics of North America|November 25, 2010
Novel anticancer agents in clinical trials for well-differentiated neuroendocrine tumorsSandrine Faivre, Marie-Paule Sablin, Chantal Dreyer, et al.
Lung Cancer (Amsterdam, Netherlands)|October 11, 2007
Could we expect to improve survival in small cell lung cancer?Ghassan El Maalouf, Jean-Michel Rodier, Sandrine Faivre, et al.
Therapie|June 22, 2007
[Irinotecan and liver dysfunctions]Marie-Paule Sablin, Christophe Le Tourneau, Sandrine Faivre, et al.
Presse Medicale (Paris, France : 1983)|April 10, 2010
[Targeted therapies in hepatocellular carcinoma]Mohamed Bouattour, Hélène Marijon, Chantal Dreyer, et al.
Molecular Cancer Therapeutics|December 7, 2002
Cellular and molecular pharmacology of oxaliplatinEric Raymond, Sandrine Faivre, Stephen Chaney, et al.
La Revue Du Praticien|January 5, 2011
[Targeted therapies in colorectal cancer]Marie-Paule Sablin, Chantal Dreyer, Camélia Colichi, et al.
Biochemical Pharmacology|June 27, 2003
DNA strand breaks and apoptosis induced by oxaliplatin in cancer cellsSandrine Faivre, Denise Chan, Richard Salinas, et al.
Bulletin Du Cancer|July 12, 2011
[PI3K-AKT-mTOR pathway and cancer]Laetitia Coutte, Chantal Dreyer, Marie-Paule Sablin, et al.
Annals of Surgical Oncology|April 14, 2009
Preoperative liver hypertrophy induced by portal flow occlusion before major hepatic resection for colorectal metastases can be impaired by bevacizumabBéatrice Aussilhou, Safi Dokmak, Sandrine Faivre, et al.
Pageof 14